Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses

TheSLCO1B1rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications

(2011) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health Organization Recommendations

(2011) S. Thee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients

(2011) Justin J. Wilkins et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Pharmacogenetics of NAT2 Enzyme Maturation in Perinatally HIV Exposed Infants Receiving Isoniazid

(2011) Rui Zhu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Arylamine N-Acetyltransferase 2 (NAT2) Genetic Diversity and Traditional Subsistence: A Worldwide Population Survey

(2011) Audrey Sabbagh et al.   PLoS One

Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations

(2010) M. Weiner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

PYRAZINAMIDE PLASMA CONCENTRATIONS IN YOUNG CHILDREN WITH TUBERCULOSIS

(2010) Helen McIlleron et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

(2009) Hendrik Simon Schaaf et al.   BMC Medicine

Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines

(2009) Helen McIlleron et al.   CLINICAL INFECTIOUS DISEASES

Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana

(2009) Sekai Chideya et al.   CLINICAL INFECTIOUS DISEASES

Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans

(2009) Brian J. Anderson et al.   Drug Metabolism and Pharmacokinetics

Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption

(2008) J. J. Wilkins et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics

(2007) B.J. Anderson et al.   Annual Review of Pharmacology and Toxicology